Ovid Therapeutics Inc (OVID) Shares Likely to Appreciate Into Catalyst Rich 2020 - RBC Capital
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $12.00 price target on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
